Evidence map›Paper›PMID 34589398›Full record

ReviewActa pharmaceutica Sinica. B2021

Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies.

Peng Liu, Caifang Gao, Hongguo Chen, Chi Teng Vong, Xu Wu, Xudong Tang, Shengpeng Wang, Yitao Wang

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Exploring multiple drug actions of a CaNaunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Peng LiuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.
Caifang GaoState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.
Hongguo ChenState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.
Chi Teng VongState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.
Xu WuLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Xudong TangDepartment of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Shengpeng WangState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.
Yitao WangState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.
University of Macau · MOChinese Academy of Medical Sciences & Peking Union Medical College · CNSouthwest Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic intestinal disease with painful clinical manifestations and high risks of cancerization. With no curative therapy for IBD at present, the development of effective therapeutics is highly advocated. Drug delivery systems have been extensively studied to transmit therapeutics to inflamed colon sites through the enhanced permeability and retention (EPR) effect caused by the inflammation. However, the drug still could not achieve effective concentration value that merely utilized on EPR effect and display better therapeutic efficacy in the inflamed region because of nontargeted drug release. Substantial researches have shown that some specific receptors and cell adhesion molecules highly expresses on the surface of colonic endothelial and/or immune cells when IBD occurs, ligand-modified drug delivery systems targeting such receptors and cell adhesion molecules can specifically deliver drug into inflamed sites and obtain great curative effects. This review introduces the overexpressed receptors and cell adhesion molecules in inflamed colon sites and retrospects the drug delivery systems functionalized by related ligands. Finally, challenges and future directions in this field are presented to advance the development of the receptor-mediated targeted drug delivery systems for the therapy of IBD.

Indexed as

ACQ, aggregation-caused quenchingActive targetADR, adverse drug reactionAIE, aggregation-induced emissionBSA, bovine serum albuminCAM, cell adhesion moleculeCD, Crohn's diseaseCell adhesion moleculeCRD, cysteine-rich domainCrohn's diseaseCS, chondroitin sulfateCT, computed tomographyCTLD, c-type lectin-like domainDCs, dendritic cellsDrug deliveryDSS, dextran sulfate sodium saltEGF, epidermal growth factorEPR, enhanced permeability and retentionFNII, fibronectin type II domainFRET, fluorescence resonance energy transferFR, folate receptorGIT, gastrointestinal tractHA, hyaluronic acidHUVEC, human umbilical vein endothelial cellsIBD, inflammatory bowel diseaseICAM, intercellular adhesion moleculeInflammatory bowel diseaseLMWC, low molecular weight chitosanLPS, lipopolysaccharideMAP4K4, mitogen-activated protein kinase kinase kinase kinase 4MGL, macrophage galactose lectinMPO, myeloperoxidaseMPS, mononuclear phagocyte systemMRI, magnetic resonance imagingMR, mannose receptorPAMAM, poly(amidoamine)PEI, polyethyleniminePepT1, peptide transporter 1PSGL-1, P-selectin glycoprotein ligand-1QDs, quantum dotsReceptor-mediated targetRES, reticuloendothelial systemTargeted therapyTfR, transferrin receptorUC, ulcerative colitisUlcerative colitisVCAM, vascular cell adhesion molecule

Identifiers

PMID34589398
PMCPMC8463263
OpenAlexW3095291274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.